F. Hodi, O. Day, S. Mcdermott, and D. , Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, New England Journal of Medicine, vol.363, issue.8, pp.711-723, 2010.
DOI : 10.1056/NEJMoa1003466
URL : http://www.nejm.org/doi/pdf/10.1056/NEJMoa1003466

K. Mahoney, G. Freeman, and D. Mcdermott, The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma, Clinical Therapeutics, vol.37, issue.4, pp.764-782, 2015.
DOI : 10.1016/j.clinthera.2015.02.018
URL : http://europepmc.org/articles/pmc4497957?pdf=render

L. Fecher, S. Agarwala, and F. Hodi, Ipilimumab and Its Toxicities: A Multidisciplinary Approach, The Oncologist, vol.18, issue.6, pp.733-743, 2013.
DOI : 10.1634/theoncologist.2012-0483
URL : http://theoncologist.alphamedpress.org/content/18/6/733.full.pdf

S. Hwang, G. Carlos, and D. Wakade, Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort, Journal of the American Academy of Dermatology, vol.74, issue.3, pp.455-461, 2016.
DOI : 10.1016/j.jaad.2015.10.029

J. Weber, K. Hauschild, and A. , Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab, Journal of Clinical Oncology, vol.30, issue.21, pp.2691-2697, 2012.
DOI : 10.1200/JCO.2012.41.6750

D. Vittoria-scarpati, G. Fusciello, C. Perri, and F. , Ipilimumab in the treatment of metastatic melanoma: management of adverse events, OncoTargets and Therapy, vol.7, pp.203-209, 2014.
DOI : 10.2147/OTT.S57335

T. Gangadhar and R. Vonderheide, Mitigating the toxic effects of anticancer immunotherapy, Nature Reviews Clinical Oncology, vol.90, issue.2, pp.91-99, 2014.
DOI : 10.1056/NEJMe1305484

M. Sanlorenzo, I. Vujic, and A. Daud, Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression, JAMA Dermatology, vol.151, issue.11, pp.1206-1212, 2015.
DOI : 10.1001/jamadermatol.2015.1916
URL : http://archderm.jamanetwork.com/data/journals/derm/934672/doi150027.pdf

T. Horvat, N. Adel, and T. Dang, Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center, Journal of Clinical Oncology, vol.33, issue.28, pp.3193-3198, 2015.
DOI : 10.1200/JCO.2015.60.8448
URL : http://europepmc.org/articles/pmc5087335?pdf=render

L. Spain, S. Diem, and J. Larkin, Management of toxicities of immune checkpoint inhibitors, Cancer Treatment Reviews, vol.44, pp.51-60, 2016.
DOI : 10.1016/j.ctrv.2016.02.001

J. Michot, C. Bigenwald, and S. Champiat, Immune-related adverse events with immune checkpoint blockade: a comprehensive review, European Journal of Cancer, vol.54, pp.139-148, 2016.
DOI : 10.1016/j.ejca.2015.11.016

S. Andrews and R. Holden, Characteristics and management of immunerelated adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma, Cancer Manag Res, vol.4, pp.299-307, 2012.
DOI : 10.2147/cmar.s31873
URL : https://www.dovepress.com/getfile.php?fileID=13923

M. Callahan, M. Postow, and J. Wolchok, Immunomodulatory therapy for melanoma: Ipilimumab and beyond, Clinics in Dermatology, vol.31, issue.2, pp.191-199, 2013.
DOI : 10.1016/j.clindermatol.2012.08.006
URL : http://europepmc.org/articles/pmc3653249?pdf=render

J. Munoz, B. Guillot, and C. Girard, First report of ipilimumab-induced Grover disease, British Journal of Dermatology, vol.26, issue.5, pp.1236-1237, 2014.
DOI : 10.1111/dth.12027

S. Jaber, E. Cowen, and L. Haworth, Skin reactions in a subset of patients with stage IV melanoma treated with anticytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent, Arch Dermatol, vol.142, pp.166-172, 2006.